160 related articles for article (PubMed ID: 7681461)
1. Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity.
Kurokawa H; Tsuru S; Okada M; Nakamura T; Kajiyama M
Int J Oral Maxillofac Surg; 1993 Feb; 22(1):35-8. PubMed ID: 7681461
[TBL] [Abstract][Full Text] [Related]
2. Combination assay for tumor markers in oral squamous cell carcinoma.
Kurokawa H; Yamashita Y; Tokudome S; Kajiyama M
J Oral Maxillofac Surg; 1997 Sep; 55(9):964-6. PubMed ID: 9294507
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125.
Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M
Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320
[TBL] [Abstract][Full Text] [Related]
5. SCCA, TSGF, and the Long Non-Coding RNA AC007271.3 are Effective Biomarkers for Diagnosing Oral Squamous Cell Carcinoma.
Shao T; Huang J; Zheng Z; Wu Q; Liu T; Lv X
Cell Physiol Biochem; 2018; 47(1):26-38. PubMed ID: 29763905
[TBL] [Abstract][Full Text] [Related]
6. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma.
Kimura Y; Fujieda S; Takabayashi T; Tanaka T; Sugimoto C; Saito H
Cancer Lett; 2000 Jul; 155(2):163-8. PubMed ID: 10822131
[TBL] [Abstract][Full Text] [Related]
7. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
8. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
9. Use of tumor markers in the management of head and neck cancer.
Rosati G; Riccardi F; Tucci A
Int J Biol Markers; 2000; 15(2):179-83. PubMed ID: 10883893
[TBL] [Abstract][Full Text] [Related]
10. [The diagnostic value of the tumor markers CEA, "Ca 19-9", "Ca 125", "Ca15-3" and "SCC" for the detection of recurrent tumors in patients with tumors of the head and neck].
Zöller J; Fiehn W; Mende U; Hotz G
Dtsch Z Mund Kiefer Gesichtschir; 1990; 14(4):254-9. PubMed ID: 2134649
[TBL] [Abstract][Full Text] [Related]
11. Serum SCCA, Cyfra 21-1, EGFR and Cyclin D1 levels in patients with oral squamous cell carcinoma.
Feng XY; Li JH; Li JZ; Han ZX; Xing RD
Int J Biol Markers; 2010; 25(2):93-8. PubMed ID: 20586028
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.
Sheng X; Du X; Zhang X; Li D; Lu C; Li Q; Ma Z; Song Q; Wang C
Croat Med J; 2009 Oct; 50(5):455-64. PubMed ID: 19839069
[TBL] [Abstract][Full Text] [Related]
13. Tumor markers in patients with chronic renal failure.
Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
[TBL] [Abstract][Full Text] [Related]
14. Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer.
Krimmel M; Hoffmann J; Krimmel C; Cornelius CP; Schwenzer N
J Craniomaxillofac Surg; 1998 Aug; 26(4):243-8. PubMed ID: 9777503
[TBL] [Abstract][Full Text] [Related]
15. Tumour marker detection in oesophageal carcinoma.
Mealy K; Feely J; Reid I; McSweeney J; Walsh T; Hennessy TP
Eur J Surg Oncol; 1996 Oct; 22(5):505-7. PubMed ID: 8903494
[TBL] [Abstract][Full Text] [Related]
16. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
[TBL] [Abstract][Full Text] [Related]
17. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer.
Pectasides D; Economides N; Bourazanis J; Pozadzizou P; Gogou L; Koutsiouba P; Athanassiou A
Am J Clin Oncol; 1994 Aug; 17(4):307-12. PubMed ID: 8048392
[TBL] [Abstract][Full Text] [Related]
18. [Results with the use of the SCC antigen in squamous cell carcinomas of the oral cavity].
Hellner D; Klapdor R; Gundlach KH; Schmelzle R
Dtsch Z Mund Kiefer Gesichtschir; 1989; 13(4):291-5. PubMed ID: 2637079
[TBL] [Abstract][Full Text] [Related]
19. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
20. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
